Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50

FDA places clinical hold on Astellas clinical trial focused on Pompe disease

By Brian Buntz | June 28, 2022

Astellas Pharma in the Drug Discovery & Development Pharma 50Astellas Pharma (TSE:4503) has revealed that the FDA has slapped a clinical hold on its Phase 1/2 FORTIS Pompe disease study after observing a serious adverse event (SAE) — peripheral sensory neuropathy — in a trial participant.

Peripheral sensory neuropathy results from damage to nerves outside of the central nervous system. The condition can lead to pain, numbness and weakness.

The FORTIS study had focused on the experimental adeno-associated virus gene replacement therapy AT845 in adults with late-onset Pompe disease.

Pompe disease is a rare genetic disorder associated with the buildup of glycogen in cells. The disease can lead to progressive muscle weakness and reduced life expectancy. Disease progression is associated with the age of onset.

Classic infantile-onset Pompe disease occurs in the first few months of life. Non-classic infantile-onset manifests around 1 year of age while late-onset appears after that — often in adolescence or adulthood.

FDA continues to gather information to understand the potential risks to subjects in the clinical study and is also researching the recent SAE report.

The Tokyo-based company said it would work with the site investigator to monitor the patient and will continue collecting and analyzing data.

“Patient safety is our top priority, and we are working closely with the FDA to determine appropriate next steps,” said Dr. Weston Miller, senior medical director, clinical development at Astellas Gene Therapies, in a statement. “We remain committed to the safe and effective development of AT845 and will keep the scientific and patient communities informed with updates as we learn more.”

Astellas shares were up 1.57% to ¥2,197.00.

 


Filed Under: Cardiovascular, Cell & gene therapy, Neurological Disease
Tagged With: Astellas Pharma, clinical hold, FDA, FORTIS, Pompe disease
 

Tell Us What You Think! Cancel reply

You must be logged in to post a comment.

Related Articles Read More >

Pharma50: 50 Leading Cell and gene therapy companies
50 leading cell and gene therapy companies
Clippard NIV Series media isolation valves
Clippard releases new series of isolation valves
Yan Zhang, CEO of Mission Bio explains how the company is working to drive precision medicine
How Mission Bio is working to drive precision medicine
DNA Script
DNA Script supports same-day q/dPCR with debut of next-generation SYNTAX system

Need Drug Discovery news in a minute?

We Deliver!
Drug Discovery & Development Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Medtech100 Index
  • Medical Design Sourcing
  • Subscribe to our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50